Fig. 2From: Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studiesOverall survival duration of patients in different dose cohorts for patients receiving pyrotinib, or pyrotinib plus capecitabineBack to article page